descriptive
Analysis v1
32
0
Taking saroglitazar didn't make the muscles weaker or more fatty in liver transplant patients with fatty liver disease. This finding is from the abstract summary - full study details were not available
Scientific Claim
Saroglitazar treatment did not reduce fat-free muscle volume or increase muscle fat infiltration in liver transplant recipients with NAFLD.
Original Statement
“Saroglitazar did not decrease fat-free muscle volume nor increase muscle fat infiltration”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract uses 'did not decrease' and 'did not increase', which accurately describes the observed lack of effect.
Evidence from Studies
Supporting (1)
32
32
Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients
Cross-Sectional Study
Human
2023 Sep 1Contradicting (0)
0
No contradicting evidence found